natgillin/translations-raw huggingface dataset:
obtaining a concentrate of the aqueous phase obtained in step (c); 
dobivanje koncentrata vodene faze dobivene u koraku (c);
centrifuging the concentrate obtained in step d) to obtain a supernatant; 
centrifugiranje koncentrata dobivenog u koraku d) da se dobije supernatant;
the eluate from the previous step is passed through activated charcoal columns, and said activated charcoal columns are then washed with distilled water to remove the retained pigments and impurities; phycotoxins are eluted with an elution solution; 
eluat iz prethodnog koraka se propušta kroz kolone aktivnog ugljena, i te se kolone aktivnog ugljena zatim ispiru destiliranom vodom da se uklone zadržani pigmenti i onečišćenja; fikotoksini se eluiraju s otopinom za eluaciju;
The partially purified extract from the previous step is subjected to a preparative high-performance liquid chromatography in several steps to obtain the pure biologically active phycotoxin. 
djelomično pročišćeni ekstrakt iz prethodnog koraka podvrgava se preparativnoj tekućinskoj kromatografiji visoke učinkovitosti u nekoliko koraka da se dobije čisti biološki aktivni fikotoksin.
Method according to claim 1, in which the washing solution of steps f) and h) is 50 mM acetic acid, in step (f) the columns is washed with 5 to 15 times its volume and the elution solution is an alcoholic extraction mixture. 
Postupak prema zahtjevu 1, u kojem je otopina za ispiranje u koracima f) i h) 50 mM octena kiselina, u koraku (f) kolone se ispiru volumenom koji je 5 do 15 puta veći od volumena kolone i otopina za eluaciju je alkoholna ekstrakcijska smjesa.
Method according to any one of claims 1 to 6, in which the cyanobacteria able to produce phycotoxins belong to the genera Cylindrospermopsis sp, Microcystis sp, Anabaena sp, Gomphosphaeria sp, Oscillatoria sp, Aphanizomenon sp and Lyngbya wollei. 
Postupak prema bilo kojem od zahtjeva 1 do 6, u kojem cijanobakterije mogu proizvesti fikotoksine koji pripadaju rodovima Cylindrospermopsis sp, Microcystis sp, Anabaena sp, Gomphosphaeria sp, Oscillatoria sp, Aphanizomenon sp i Lyngbya wollei.
Drag head (100) according to claim 1, wherein the suction section (110) is rotatable with respect to the heel section (111) about an axis of rotation which is in use substantially horizontal and perpendicular to the dragging direction. 
Usisna glava (100) sukladno zahtjevu 1, pri čemu je usisni odjeljak (110) rotatabilan u odnosu na stražnji odjeljak (111) oko rotacijske osi koja je u uporabi horizontalna i okomita na smjer povlačenja.
Drag head (100) according to claim 4, wherein a width of the bed engaging surface (122) of the heel section (111) corresponds substantially to a width of the cutting edge (115). 
Usisna glava (100) sukladno zahtjevu 4, pri čemu je širina površine koja međudjeluje s ležajem (122) stražnjeg dijela (111) odgovarajuća širini reznog ruba (115).
Drag head (100) according to any one of the preceding claims wherein the suction opening (113) is at least partially bounded by the heel section (111). 
Usisna glava (100) sukladno bilo kojem od prethodnih zahtjeva pri čemu je usisni otvor (113) barem djelomice ograničen stražnjim odjeljkom (111).
Vessel (4), such as a trailing suction hopper dredger, comprising a drag member and a drag head according to any one of the preceding claims wherein the heel section (111) is operatively connected to be dragged along the bed by the drag member. 
Plovilo (4), kao što je brod jaružar, koje sadrži usisni članak i usisnu glavu sukladno bilo kojem od prethodnih zahtjeva pri čemu je stražnji odjeljak (111) operativno povezan kako bi ga se moglo povlačiti duž ležaja pomoću usisnog člana.
The method according to claim 16 wherein the mixture comprises sand and water having a density of more than 1650 kg/m3. 
Postupak sukladno zahtjevu 16 pri čemu mješavina sadrži pijesak i vodu gustoće više od 1650 kg/m3.
Aqueous suspension according to claim 21 or 22, characterized in that said surface-reacted calcium carbonate has a specific surface area of more than 20 m2/g, preferably of more than 30 m2/g, and more preferably of more than 80 m2/g. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 20, naznačena time da navedeni površinski reaktivni kalcijev karbonat ima specifičnu površinu veću od 20 m2/g, poželjno veću od 30 m2/g, te poželjnije veću od 80 m2/g.
A can end lid for a can, in particular for a drink can, comprising: 
Poklopac limenke, osobito limenke za piće, koji sadrži:
Can end lid according to claim 1, wherein the peripheral wall (5) of the lid plate (2) is point symmetrical to an axis (14), and the inner surface of the ring-wall (11) as to the height thereof extends in parallel to said axis at least in an upper portion of the ring-wall. 
Poklopac limenke u skladu s patentnim zahtjevom 1, naznačen time što je periferna stijenka (5) ploče poklopca (2) točka simetrična u odnosu na os (14), a unutarnja površina prstenaste stijenke (11) se svojom visinom pruža paralelno u odnosu na navedenu os u najmanju ruku u gornjem dijelu prstenaste stijenke.
Can end lid according to claim 3 or 4, wherein the ring-wall (11) extends down beyond an inner surface (16) of the ring bead (15). 
Poklopac limenke u skladu s patentnim zahtjevom 3 ili 4, naznačen time što se prstenasta stijenka (11) pruža na dolje preko unutarnje površine (16) prstenastog nabora (15).
Can end lid according to claim 7, wherein the lid plate (2) includes an area (19) surrounding the ring-wall (11) that is sloped correspondingly to the upper surface of the pedestal elevation (18). 
Poklopac limenke u skladu s patentnim zahtjevom 7, naznačen time što ploča poklopca (2) uključuje područje (19) koje okružuje prstenastu stijenku (11), koja je tako nagnuta da odgovara gornjoj površini podloge uzvišenja (18).
Can end lid according to any of claims 1 to 10, wherein the outer surface and the underside (29) of the sealing attachment (25) are in form and dimension complementary to a lid area formed by the inner surface of the ring-wall (11) and by the upper side of the break-away area (7). 
Poklopac limenke u skladu s bilo kojim od patentnim zahtjevima 1 do 10, naznačen time što vanjska površina i donja strana (29) brtvenog spoja (25) su u obliku i s dimenzijama komplementarnim području poklopca koje oblikuju unutarnja površina prstenaste stijenke (11) i gornja strana područja kidanja (7).
Can end lid according to any of claims 1 to 12, wherein the grip portion (22) in the closing rotating position of the opening tab (20) extends close to the peripheral wall (5) of the lid plate and is extended on either side thereof in an area adjacent to the peripheral wall (5). 
Poklopac limenke u skladu s bilo kojim od patentnim zahtjevima 1 do 12, naznačen time što se dio za uhvat (22) u zatvarajućem okretljivom položaju jezičca za otvaranje (20) pruža u blizinu periferne stijenke (5) ploče poklopca, te se pruža na svoje obje straneu području uz perifernu stijenku (5).
reacting a compound of formula with a suitable compound of formula to a compound of formulas or wherein the substituents are described in claim 1, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts, or 
[image] s prikladnim spojem formule: [image] za dobivanje spoja sljedećih formula: [image] [image] pri čemu su supstituenti opisani u zahtjevu 1, ili po želji, pretvaranje spojeva koji su dobiveni u farmaceutski prikladne kiselinske adicijske soli, ili
reacting a compound of formulas with a suitable compound of formula to a compound of formulas or wherein the substituents are described in claim 1, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts, or 
[image] s prikladnim spojem formule: [image] za dobivanje spoja sljedećih formula: [image] [image] pri čemu su supstituenti odabrani u zahtjevu 1, ili po želji, pretvaranje dobivenih spojeva u farmaceutski prikladne kiselinske adicijske soli, ili
A pharmaceutical composition comprising at least one of the compounds according to any one of claims 1 to 4 as well as its pharmaceutically acceptable salt. 
Farmaceutski sastav, naznačen time, da on obuhvaća spojeve prema bilo kojem od zahtjeva 1 do 4, kao i njihovu farmaceutski prikladnu sol.
said acid(s) of step b) each having a pKa of greater than 2.5 and less than or equal to 7, when measured at 20°C, associated with the ionisation of their first available hydrogen, and a corresponding anion formed on loss of this first available hydrogen capable of forming water-soluble calcium salts and wherein said water-soluble acid(s) are selected from the group consisting of acetic acid, formic acid, propanoic acid and mixtures thereof; 
navedena kiselina(e) iz koraka b) koja svaka ima pKa veći od 2.5 i manji od ili jednak 7, mjereno na 20°C, povezana je s ionizacijom njezinog prvog slobodnog vodika, te odgovarajući anion stvoren gubitkom tog prvog slobodnog vodika može tvoriti u vodi topive kalcijeve soli i pri čemu se navedena u vodi topiva kiselina(e) odabire iz skupine koju čine octena kiselina, mravlja kiselina, propanska kiselina i njihove smjese;
Aqueous suspension according to claim 1, characterized in that said GNCC is selected from the group consisting of marble, chalk, calcite, dolomite, limestone and mixtures thereof. 
Vodena suspenzija prema zahtjevu 1, naznačena time da je navedeni GNCC odabran iz skupine koja sadrži mramor, kredu, kalcit, dolomit, vapnenac i njihove smjese.
Aqueous suspension according to any of claims 1 to 7, characterized in that said water-soluble acid(s) are selected from the group consisting of acetic acid, formic acid and mixtures thereof, and preferably is acetic acid. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 7, naznačena time da je navedena u vodi topiva kiselina(e) odabrana iz skupine koja sadrži octenu kiselinu, mravlju kiselinu i njihove smjese, te je poželjno octena kiselina.
Aqueous suspension according to any of claims 1 to 9, characterized in that said water-soluble acid(s) of step b) are dosed in a total amount corresponding to 5 to 40 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), more preferably in a total amount corresponding to 10 to 30 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), and most preferably in a total amount corresponding to 15 to 25 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a). 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 9, naznačena time da se navedena u vodi topiva kiselina(e) iz koraka b) dozira u ukupnoj količini koja odgovara 5 do 40 tež.-% ekvivalenata čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), poželjnije u ukupnoj količini koja odgovara od 10 do 30 tež.-% ekvivalenata čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), te najpoželjnije u ukupnoj količini koja odgovara od 15 do 25 tež.-% ekvivalenata čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a).
Aqueous suspension according to any of claims 1 to 10, characterized in that said water-soluble acid(s) of step b) are provided in the form of an aqueous solution having an acid concentration, determined as the equivalent weight of pure acid on the weight of the total solution, corresponding to from 25 to 75 %, and more preferably to from 40 to 60 %. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 10, naznačena time da se navedena u vodi topiva kiselina(e) iz koraka b) osigurava u obliku vodene otopine koja ima kiselu koncentraciju, određenu kao ekvivalentna težina čiste kiseline prema težini ukupne otopine, koja odgovara od 25 do 75 %, te poželjnije od 40 do 60 %.
Aqueous suspension according to any of claims 1 to 11, characterized in that during step d), said acid(s) of step b) are added, in one or more steps, preferably in one step, to said GNCC. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 11, naznačena time da se tijekom koraka d), navedena kiselina(e) iz koraka b) dodaje, u jednom ili više koraka, poželjno u jednom koraku, u navedeni GNCC.
Aqueous suspension according to any of claims 1 to 13, characterized in that the anion of said water-soluble salt is selected from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, oxalate, silicate, mixtures thereof and hydrates thereof, more preferably from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof, and most preferably from the group consisting of dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 13, naznačena time da da je anion navedene soli koja je topiva u vodi odabran iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, oksalat, silikat, njihove smjese i njihove hidrate, poželjnije iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, njihove smjese i njihove hidrate, te je najpoželjnije iz skupine koja sadrži dihidrogen fosfat, monohidrogen fosfat, njihove smjese i njihove hidrate.
Aqueous suspension according to any of claims 1 to 14, characterized in that the anion of said water-soluble salt(s) is dosed in a total amount corresponding to at least 5 x 10-5 mol of anion/m2 GNCC provided in step a), preferably in a total amount corresponding to 5 x 10-5 to 50 x 10-5 mol of anion/m2 GNCC provided in step a), and more preferably in a total amount corresponding to 10 x 10-5 to 30 x 10-5 mol of anion/m2 GNCC provided in step a). 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 14, naznačena time da se anion navedene u vodi topive soli ili topivih soli dozira u ukupnoj količini koja odgovara barem 5 x 10-5 mol anion/m2 GNCC osiguranog u koraku a), poželjno u ukupnoj količini koja odgovara 5 x 10-5 do 50 x 10-5 mol anion/m2 GNCC osiguranog u koraku a), te poželjnije u ukupnoj količini koja odgovara 10 x 10-5 do 30 x 10-5 mol anion/m2 GNCC osiguranog u koraku a).
Aqueous suspension according to any of claims 1 to 20, characterized in that said surface-reacted calcium carbonate has a specific surface area of more than 20 m2/g, preferably of more than 30 m2/g, and more preferably of more than 80 m2/g. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 20, naznačena time da navedeni površinski reaktivni kalcijev karbonat ima specifičnu površinu veću od 20 m2/g, poželjno veću od 30 m2/g, te poželjnije veću od 80 m2/g.
A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier diluent, or excipient, for use in therapy. 
Farmaceutski pripravak, koji sadrži protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar, naznačen time što je namijenjen upotrebi u terapiji.
A cytotoxic compound comprising a linking group with a reactive group bonded thereto capable of covalently linking the cytotoxic compound to a cell binding agent (CBA), wherein said cytotoxic compound is represented by the following formula: or a pharmaceutically acceptable salt thereof, wherein: 
Citotoksični spoj koji obuhvaća veznu skupinu i na nju vezanu reaktivnu skupinu koja može kovalentno vezati citotoksični spoj za sredstvo za vezanje stanica (engl. cell binding agent, CBA), gdje je taj citotoksični spoj predstavljen bilo kojom od sljedećih formula:
L', L", and L'" are the same or different, and are independently selected from -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit - (OCH2CH2)n-Rc, halogen, guanidinium [-NH(C=NH)NH2], -OR, -NR'R",-NO2, -NR'COR", -SR, a sulfoxide represented by -SOR', a sulfone represented by -SO2R', a sulfonate -SO3M, a sulfate -OSO3M, a sulfonamide represented by -SO2NR'R", cyano, an azido, -COR', -OCOR', -OCONR'R" and the linking group with the reactive group bonded thereto, provided only one of L', L", and L"' is the linking group with the reactive group bonded thereto; and 
[image] ili njegova farmaceutski prikladna sol, gdje: L', L" i L"' su jednaki ili različiti, i nezavisno su izabrani između -H, po izboru supstituirani linearni, razgranati ili ciklički alkil, alkenil ili alkinil s 1 do 10 atoma ugljika, jedinica polietilen glikola (-OCH2CH2)n-Rc, halogen, gvanidin [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NR'COR", -SR, sulfoksid predstavljen s -SOR', sulfon predstavljen s -SO2R', sulfonat -SO3M, sulfat -OSO3M, sulfonamid predstavljen s -SO2NR'R", cijano, azid, -COR', -OCOR', -OCONR'R" i vezna skupina s vezanom reaktivnom skupinom na sebi; uz uvjet da je samo jedan od L', L" i L"' vezna skupina s vezanom reaktivnom skupinom; i G je izabran između -CH- ili -N-.
A conjugate comprising: a cytotoxic compound and a cell binding agent (CBA), wherein the cytotoxic compound comprises a linking group which covalently links the cytotoxic compound to the CBA, and wherein said cytotoxic compound is represented by the following formula: or a pharmaceutically acceptable salt thereof, wherein: 
Konjugat koji obuhvaća: citotoksični spoj i sredstvo za vezanje stanica (CBA), gdje citotoksični spoj ima veznu skupinu koja kovalentno veže citotoksični spoj za CBA, i gdje je taj citotoksični spoj predstavljen bilo kojom od sljedećih formula: [image] ili njegova farmaceutski prikladna sol, gdje:
A process for producing a lyophilized preparation containing a crystal of a meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, comprising the steps: 
Postupak proizvodnje liofiliziranog pripravka koji sadrži kristal megluminske soli 6- fluoro-3-hidroski-2-pirazinkarboksamida, naznačen time, da se postupak sastoji od sljedećih koraka:
cooling the frozen product again; and 
ponovnog hlađenja kristalnog zamrznutog produkta; i
An amyloid beta peptide comprising the amino acid sequence L-V-F-F-C corresponding to amino acids 17 to 21 of SEQ ID NO:4 and the amino acid sequence C-I-I-G-L-M-V corresponding to amino acids 30 to 36 of SEQ ID NO:4, said amyloid beta peptide further comprising a disulfide bond between cysteine residues corresponding to amino acids 21 and 30 of SEQ ID NO:4, or a variant of said amyloid beta peptide wherein one, two, three, four, or five amino acids have been replaced by conservative substitution, one, two, three, four, or five amino acids have been deleted, or one, two, three, four, or five amino acids have been inserted, said amyloid beta peptide or said variant of said amyloid beta peptide having exactly two cysteines, said cysteines corresponding to Cys21 and Cys30 in SEQ ID NO:4. 
Amiloidni beta peptid koji sadrži sekvencu amino kiseline L-V-F-F-C koja odgovara amino kiselinama 17 do 21 iz SEQ ID NO:4 i sekvencu amino kiseline C-I-I-G-L-M-V koja odgovara amino kiselinama 30 do 36 iz SEQ ID NO:4, te navedeni amiloidni beta peptid nadalje sadrži disulfidnu vezu između cisteinskih ostataka koja odgovara amino kiselinama 21 i 30 iz SEQ ID NO:4, ili varijantu navedenog amiloidnog beta peptida naznačen time da su jedna, dvije, tri, četiri, ili pet amino kiselina zamijenjene s konzervativnom supstitucijom, da je izbrisana jedna, dvije, tri, četiri, ili pet amino kiselina, ili je umetnuta jedna, dvije, tri, četiri, ili pet amino kiselina, navedeni amiloidni beta peptid ili navedena varijanta navedenog amiloidnog beta peptida ima točno dva cisteina, te navedeni cisteini odgovaraju Cys21 i Cys30 iz SEQ ID NO:4.
An amyloid beta peptide according to claim 1 comprising the amino acid sequence L-V-F-F-C-E-D-V-G-S-N-K-G-C-I-I-G-L-M-V corresponding to amino acids 17 to 36 of SEQ ID NO:4, or a variant of said amyloid beta peptide wherein one, two, three, four, or five amino acids have been replaced by conservative substitution, one, two, three, four, or five amino acids have been deleted, or one, two, three, four, or five amino acids have been inserted. 
Amiloidni beta peptid prema zahtjevu 1 koji sadrži sekvencu amino kiseline L-V-F-F-C-E-D-V-G-S-N-K-G-C-I-I-G-L-M-V koja odgovara amino kiselinama 17 do 36 iz SEQ ID NO:4, ili varijanti navedenog amiloidnog beta peptida naznačen time da su jedna, dvije, tri, četiri, ili pet amino kiselina zamijenjene s konzervativnom supstitucijom, izbrisana je jedna, dvije, tri, četiri, ili pet amino kiselina, ili je umetnuta jedna, dvije, tri, četiri, ili pet amino kiselina.
An amyloid beta peptide according to claim 2 comprising the amino acid sequence SEQ ID NO:4, or an amino acid sequence comprising amino acids 1 to 40 of SEQ ID NO:4, or a variant of said amyloid beta peptide wherein one, two, three, four, or five amino acids have been replaced by conservative substitution, one, two, three, four, or five amino acids have been deleted, or one, two, three, four, or five amino acids have been inserted. 
Amiloidni beta peptid prema zahtjevu 2 naznačen time da sadrži sekvencu amino kiseline SEQ ID NO:4, ili sekvencu amino kiseline koja sadrži amino kiseline 1 do 40 iz SEQ ID NO:4, ili varijantu navedenog amiloidnog beta peptida naznačen time da su jedna, dvije, tri, četiri, ili pet amino kiselina zamijenjene s konzervativnom supstitucijom, izbrisana je jedna, dvije, tri, četiri, ili pet amino kiselina, ili je umetnuta jedna, dvije, tri, četiri, ili pet amino kiselina.
one or two terminal amino acids have been maleimidated; 
su jedna ili dvije terminalne amino kiseline bile maleimidirane;
the C-terminal amino acid has been amidated. 
je C-terminalna amino kiselina bila amidirana.
providing a test compound, 
osiguravanje testnog spoja,
identifying said test compound as suitable for the treatment of said disease if said test compound binds to said amyloid peptide and/or inhibits formation of peptide oligomers as determined in step (c). 
identificiranje navedenog testnog spoja kao pogodnog za liječenje navedene bolesti ako se navedeni testni spoj veže na navedeni amiloidni beta peptid i/ili inhibira stvaranje peptidnih oligomera kako je određeno u koraku (c).
The method according to claim 9, wherein said binding protein is selected from an antibody fragment, such as a Fab fragment, a (Fab)2 fragment, a single chain Fab fragment, a single chain Fv fragment, a single chain Fv dimer, engineered non-natural receptor derivatives, such as derivatives of the anticalin, an Affibody, FNfn10, neocarzinostatin, ankyrin repeat protein, PDH finger, CDR3 grafted green fluorescent protein, and E. coli periplasmic binding protein scaffolds. 
Postupak prema zahtjevu 9, naznačen time da je navedeni vezujući protein odabran od fragmenta protutijela, kao što je Fab fragment, (Fab)2 fragment, jednolančani Fab fragment, jednolančani Fv fragment, jednolančani Fv dimer, konstruirane derivate ne-prirodnih receptora, kao što su derivati antikalina, Affibody, FNfn10, neokarzinostatin, ankirin ponavljajući protein, PDH finger, CDR3 presađeni zeleni fluorescentni protein, te E. coli periplazmatski nosači vezivnih proteina.
the amino acid alanine in position 692, as defined by the sequence of the human APP in SEQ ID NO:12 or the corresponding position in a homologous or heterologous APP, is replaced with a cysteine, wherein the homologous or heterologous APP is an APP derived from an animal or a synthetic, mutated and/or non-naturally occurring APP having a sequence identity of at least 80 %, such as at least 90 %, or at least 95 % as compared to the human APP in SEQ ID NO:12, ii) the amino acid alanine in position 701, as defined by said sequence of said human APP in SEQ ID NO:12 or said corresponding position in said homologous or heterologous APP, is replaced with a cysteine, and iii) said APP has exactly two cysteines. 
alanin amino kiseline na položaju 692, kako je definirano sa sekvencom ljudskog APP u SEQ ID NO:12 ili na odgovarajućem položaju u homolognom ili heterolognom APP, se zamjenjuje s cisteinom, pri čemu homologni ili heterologni APP je APP dobiven od životinjskog ili sintetskog, mutiranog APP i/ili APP koji se ne pojavljuje u prirodi koji ima identičnost sekvence od barem 80 %, kao što je barem 90 %, ili barem 95 % u usporedbi s ljudskim APP u SEQ ID NO:12, ii) alanin amino kiseline na položaju 701, kako je definirano s navedenom sekvencom ljudskog APP u SEQ ID NO:12 ili na navedenom odgovarajućem položaju u navedenom homolognom ili heterolognom APP, se zamjenjuje s cisteinom, te iii) navedeni APP ima točno dva cisteina.